Chifu

Chifu-Bio is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on selective kinase inhibitors for the treatment of autoimmune diseases, inflammatory conditions, and oncology. Its lead programs include highly selective JAK inhibitors designed to improve safety profiles compared to first-generation pan-JAK inhibitors. Chifu-Bio leverages its internal medicinal chemistry expertise to advance a pipeline of candidates through early to mid-stage clinical trials. The company aims to address significant unmet medical needs in the global market through precision medicine approaches.